158 related articles for article (PubMed ID: 9536956)
1. Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients.
Stanley AJ; Bouchier IA; Hayes PC
Gut; 1998 Feb; 42(2):283-7. PubMed ID: 9536956
[TBL] [Abstract][Full Text] [Related]
2. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
[TBL] [Abstract][Full Text] [Related]
3. Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5-mononitrate on portal flow and splanchnic arterial circulation in cirrhosis.
Piscaglia F; Gaiani S; Siringo S; Gramantieri L; Serra C; Bolondi L
Aliment Pharmacol Ther; 1998 May; 12(5):475-81. PubMed ID: 9663729
[TBL] [Abstract][Full Text] [Related]
4. Early identification of haemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with 'high-risk' varices.
Sharma P; Kumar A; Sharma BC; Sarin SK
Aliment Pharmacol Ther; 2009 Jul; 30(1):48-60. PubMed ID: 19392862
[TBL] [Abstract][Full Text] [Related]
5. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis.
Bellis L; Berzigotti A; Abraldes JG; Moitinho E; García-Pagán JC; Bosch J; Rodés J
Hepatology; 2003 Feb; 37(2):378-84. PubMed ID: 12540788
[TBL] [Abstract][Full Text] [Related]
6. Endoscopic assessment of variceal volume and wall tension in cirrhotic patients: effects of pharmacological therapy.
Escorsell A; Bordas JM; Feu F; García-Pagán JC; Ginès A; Bosch J; Rodés J
Gastroenterology; 1997 Nov; 113(5):1640-6. PubMed ID: 9352867
[TBL] [Abstract][Full Text] [Related]
7. [Propranolol and 5-isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events].
Castaño G; Viudez P; Sookoian S; Carlevaro O; Riccitelli M; Frider B
Gastroenterol Hepatol; 2000; 23(6):275-81. PubMed ID: 15324622
[TBL] [Abstract][Full Text] [Related]
8. Effects of 5-isosorbide mononitrate and propranolol on subclinical hepatic encephalopathy and renal function in patients with liver cirrhosis.
Silva G; Segovia R; Ponce R; Backhouse C; Palma M; Roblero JP; Abadal J; Quijada C; Troncoso M; Iturriaga H
Hepatogastroenterology; 2002; 49(47):1357-62. PubMed ID: 12239942
[TBL] [Abstract][Full Text] [Related]
9. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension.
Albillos A; García-Pagán JC; Iborra J; Bandi JC; Cacho G; Pérez-Paramo M; Escorsell A; Calleja JL; Escartín P; Bosch J
Gastroenterology; 1998 Jul; 115(1):116-23. PubMed ID: 9649466
[TBL] [Abstract][Full Text] [Related]
10. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA
Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651
[TBL] [Abstract][Full Text] [Related]
11. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728
[TBL] [Abstract][Full Text] [Related]
12. Differing actions of the acute administration of propranolol and isosorbide-5-mononitrate on the portal circulation.
Forrest EH; Jalan R; Redhead DN; Hayes PC
Aliment Pharmacol Ther; 1996 Oct; 10(5):795-800. PubMed ID: 8899089
[TBL] [Abstract][Full Text] [Related]
13. Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis.
Kong DR; Ma C; Wang M; Wang JG; Chen C; Zhang L; Hao JH; Li P; Xu JM
World J Gastroenterol; 2013 Jul; 19(26):4228-33. PubMed ID: 23864788
[TBL] [Abstract][Full Text] [Related]
14. Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients.
Bolognesi M; Sacerdoti D; Merkel C; Gatta A
J Ultrasound Med; 1994 Dec; 13(12):945-52. PubMed ID: 7877205
[TBL] [Abstract][Full Text] [Related]
15. Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis.
Jones AL; Bangash IH; Walker J; Simpson KJ; Finlayson ND; Hayes PC
Gut; 1995 Jan; 36(1):104-9. PubMed ID: 7890211
[TBL] [Abstract][Full Text] [Related]
16. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.
Grose RD; Plevris JN; Redhead DN; Bouchier IA; Hayes PC
J Hepatol; 1994 Apr; 20(4):542-7. PubMed ID: 8051395
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.
Garcia-Pagán JC; Navasa M; Bosch J; Bru C; Pizcueta P; Rodés J
Hepatology; 1990 Feb; 11(2):230-8. PubMed ID: 2307401
[TBL] [Abstract][Full Text] [Related]
18. The effect of a combined treatment with propranolol and isosorbide-5-mononitrate on Doppler ultrasound parameters in patients with cirrhosis and portal hypertension.
Orban Schiopu AM; Balas BI; Diculescu M
Rom J Gastroenterol; 2005 Jun; 14(2):123-7. PubMed ID: 15990930
[TBL] [Abstract][Full Text] [Related]
19. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.
García-Pagán JC; Feu F; Bosch J; Rodés J
Ann Intern Med; 1991 May; 114(10):869-73. PubMed ID: 2014947
[TBL] [Abstract][Full Text] [Related]
20. Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension.
Piscaglia F; Donati G; Gaiani S; Gramantieri L; Leoni S; Mancini M; Bolondi L
Dig Liver Dis; 2004 Sep; 36(9):594-602. PubMed ID: 15460844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
